1. Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos M, Peterson BA (1997) Phase II trial of Docetaxel in non-Hodgkin's lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 15(10): 3275–3279
2. Crown J (1999) Phase III randomized trials of Docetaxel in patients with metastatic breast cancer. Semin Oncol 26(3, Suppl 8): 33–38
3. El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW (2000) VEDex (vincristine, epirubicin, dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma. Int J Oncol 16: 777–782
4. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalmen L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of Docetaxel versus Vinorelbine or Ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18(12): 2354–2362.
5. Gandara DR, Edelman MJ, Lau D (1999) Emerging role of Docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol 26(3, Suppl 10): 3–7